期刊文献+

持续静脉输注盖诺联合顺铂治疗晚期乳腺癌疗效及毒性观察 被引量:7

Clinical observation of gainuo administered by continuous infusion with cisplation for advanced breast cancer
暂未订购
导出
摘要 评价持续静脉输注盖诺联合顺铂方案治疗晚期乳腺癌的疗效及毒性反应。方法 盖诺6mg .(m2 .d) - 1静脉注射 15min ,第 1d ,接着 ,盖诺 6mg .(m2 .d) - 1持续静脉输注 2 4h ,第 1~ 5d ;顺铂 4 0mg .d- 1静脉滴注 2h ,第 1~ 3d。结果  36例晚期乳腺癌 (均为复治病例 ) ,完全缓解 (CR) 2例 ,部分缓解 14例 ,总有效率 4 4.4 %。疗效与肿瘤转移部位及转移器官数目之间无明显相关性。毒性反应主要表现为骨髓抑制及脱发。结论 持续静脉输注盖诺联合顺铂方案治疗晚期乳腺癌疗效较好 ,毒性反应能够耐受 ,值得临床进一步使用。 Objective This clinical trail is to evaluate the response and side effect of Gainuo administered by continuous infusion with Cisplatin for advanced breast cancer.Methods Gainuo 6mg.(m 2 .d) \|1 bolus in 15\|minute i.v. infusion,followed by 6mg.(m 2 .d) \|1 ,in 24\|hour i.v. infusion(Days 1~5). Cisplation 40mg.d \|1 ,in 2\|hour i.v. infusion(Days 1~3).The regimen was repeated every 21 days.Results The completed response were 2 cases, and the partial response 14 cases,The total response rate was 44.4%(16/36).The response rate has no obviously correlation with the sites and the sums of the cancer metastatised( P >0.05). The main side effects were neutropenia and abopecia.Conclusion Gainuo administered by continuous infusion with Cisplation is an effective and well\|tolerated chemotherapy for advanced breast cancer.
出处 《肿瘤防治研究》 CAS CSCD 2002年第3期233-235,共3页 Cancer Research on Prevention and Treatment
关键词 持续静脉输注 盖诺 顺铂 治疗 晚期乳腺癌 疗效 毒性观察 联合治疗 Continuous infusion Gainuo Cisplatin Advanced breast cancer
  • 相关文献

参考文献1

共引文献91

同被引文献22

  • 1[2]Le.Chevalier T,Brisgand D,Soria JC,et al.Long term analysis of survival in the European randomized trial compariny vinorel bine/ cisplatin to vindesine/ cisplain and vinyellbine alone in advanced non-small cell lung cancer[J].Oncologist,2001,61:811
  • 2Kuwahara T,Asanami S,Kawauchi Y,et al. Experimental infusion phlebitis: tolerance Ph of peripheral vein[J]. J Toxicol, 1998,26(1):66
  • 3Kuwahara T,Asanami S. Experimental infusion phlebitis:tolerance osmolality of peripheral venous endothelial cells [J]. Nutrition, 1998,14 (6) : 496
  • 4Zhou XJ, Ramani R. Preclinical pharmacology of vinca alkaloids [J].Drags, 1992;44(Supp14):1 -5
  • 5Cros S, Wright M, Morimoto M, et al. Experimental activity of navelbline [J] Semin Oncol, 1989;16(1):15-20
  • 6Terenziani M, Demicheli R, Brambillac, et al. Vinorelbine: an active non cross-resistant drug in advanced breast cancer: results from a phase Ⅱ study. Breast cancer ReTreat, 1996;39:285-291
  • 7张载富.炎症反应[A].王迪深.病理生理学[C].北京:人民卫生出版社,1996.109-112.
  • 8Ray-Coquard I, Blay JY, Bachelot T, et al. Continuous iv infusion of vinorelbine(VNB)and bolus cisplatinum(CDDP) CIVIC regimen an efficient regimen in hormone-resistant metastatic breast cancers(MBC),after failure of anthracycline and/or paclitaxel(Meeting abstract) [J]. Proc Annu Meet Am Soc Clin Oncol,1995,14:248.
  • 9Toussaint C, Izzo J, Spielmann M, et al. Phase Ⅰ/Ⅱ trial of continuous infusion vinorelbine for advanced breast cancer [J].J Clin Oneol,1994,12(10):2102-2112.
  • 10张湘茹.长春瑞宾[A].周际昌.实用肿瘤内科学[C].北京:人民卫生出版社,1999.284-286.

引证文献7

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部